Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05005442 · ClinicalTrials.gov registry record · Phase 2
A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)
A Phase 2 study of Hematological Malignancies, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 2
- Development phase
- 192
- Enrollment target
- 20
- Study locations
NCT05005442 is a Phase 2 study of Hematological Malignancies that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 192 participants, below the 764-participant average among 16 other Hematological Malignancies trials with a reported enrollment target (75% lower). The trial reports 20 study locations across 17 states.
The verdict
NCT05005442, a Phase 2 study of Hematological Malignancies, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 192 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to determine the safety and tolerability of pembrolizumab/vibostolimab (MK-7684A) in hematological malignancies. This study will also evaluate the overall response rate (ORR), the duration of response (DOR), and disease control rate (DCR) following administration of pembrolizumab/vibostolimab. In addition, this study will characterize pharmacokinetic (PK) profile of vibostolimab (MK-7684).
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab/vibostolimab coformulation
Study Locations (20)
New Jersey
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 0004) - Hackensack
- Rutgers Cancer Institute of New Jersey ( Site 0023) - New Brunswick
Quebec
- Jewish General Hospital ( Site 0032) - Montreal
- McGill University Health Centre ( Site 0037) - Montreal
Region M. de Santiago
- Instituto Nacional del Cancer ( Site 0626) - Chile
- FALP-UIDO ( Site 0623) - Santiago
California
- City of Hope Comprehensive Cancer Center-Hematology ( Site 0024) - Duarte
Colorado
- University of Colorado Anschutz Medical Campus-The Center for Cancer and Blood Disorders ( Site 0021 - Aurora
Illinois
- University of Chicago Medical Center ( Site 0005) - Chicago
Michigan
- Henry Ford Hospital ( Site 0003) - Detroit
Texas
- University of Texas MD Anderson Cancer Center ( Site 0014) - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2021-09-28 |
| Est. Completion | 2024-12-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05005442
The ClinicalTrials.gov registry entry for NCT05005442 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 764-participant average among 16 other Hematological Malignancies trials with a reported enrollment target (75% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hematological Malignancies appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab/vibostolimab coformulation is the first listed.
NCT05005442 reports 20 study locations spanning 17 distinct geographic areas - top geographies include New Jersey, Quebec, Region M. de Santiago.
Frequently Asked Questions
What is clinical trial NCT05005442 about?
NCT05005442 is a clinical study titled "A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)". The purpose of the study is to determine the safety and tolerability of pembrolizumab/vibostolimab (MK-7684A) in hematological malignancies. This study will also evaluate the overall response rate (ORR), the duration of response (DOR), and disease control rate (DCR) following administration of pembr...
What is the current status of trial NCT05005442?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 192 participants. The study started on 2021-09-28. Estimated completion is 2024-12-10.
What conditions does trial NCT05005442 study?
This clinical trial studies the following conditions: Hematological Malignancies.
What interventions are being tested in trial NCT05005442?
The interventions under investigation include: Pembrolizumab/vibostolimab coformulation (BIOLOGICAL).
Who is sponsoring clinical trial NCT05005442?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05005442 being conducted?
This trial has 20 study locations across California, Colorado, Illinois, Michigan, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematological Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
RECRUITING · Phase 2
-
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
RECRUITING · Phase 1
-
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
RECRUITING
-
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.